Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
3
Beijing Institute for Stem Cell and Regenerative Medicine Beijing 100101 China
|
4
Institute for Stem Cell and Regeneration Chinese Academy of Sciences Beijing 100101 China
|
Publication type: Journal Article
Publication date: 2023-11-01
scimago Q1
wos Q1
SJR: 8.851
CiteScore: 39.4
Impact factor: 26.8
ISSN: 09359648, 15214095
PubMed ID:
37196221
General Materials Science
Mechanical Engineering
Mechanics of Materials
Abstract
Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of COVID‐19 mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA must enter the target cells and express sufficient proteins. Therefore, the development of effective delivery systems is necessary and crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle that has indeed accelerated mRNA applications in humans, as several mRNA‐based therapies have already been approved or are in clinical trials. In this review, we focus on mRNA‐LNP mediated anticancer therapy. We summarize the main development strategies of mRNA‐LNP formulations, discuss representative therapeutic approaches in cancer, and point out current challenges and possible future directions of this research field. We hope these delivered messages could help further improve the application of mRNA‐LNP technology in cancer therapy.
This article is protected by copyright. All rights reserved
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
|
|
|
Advanced Materials
14 publications, 4.62%
|
|
|
Journal of Controlled Release
14 publications, 4.62%
|
|
|
ACS Nano
9 publications, 2.97%
|
|
|
Advanced Science
7 publications, 2.31%
|
|
|
Vaccines
7 publications, 2.31%
|
|
|
International Journal of Molecular Sciences
6 publications, 1.98%
|
|
|
Advanced healthcare materials
6 publications, 1.98%
|
|
|
ACS applied materials & interfaces
6 publications, 1.98%
|
|
|
Materials Today Bio
6 publications, 1.98%
|
|
|
Small
5 publications, 1.65%
|
|
|
Journal of Nanobiotechnology
5 publications, 1.65%
|
|
|
Journal of the American Chemical Society
5 publications, 1.65%
|
|
|
Frontiers in Immunology
5 publications, 1.65%
|
|
|
Acta Biomaterialia
5 publications, 1.65%
|
|
|
Advanced Drug Delivery Reviews
4 publications, 1.32%
|
|
|
Biomaterials
4 publications, 1.32%
|
|
|
International Journal of Nanomedicine
4 publications, 1.32%
|
|
|
Pharmaceutics
4 publications, 1.32%
|
|
|
Journal of Materials Chemistry B
4 publications, 1.32%
|
|
|
Molecular Pharmaceutics
3 publications, 0.99%
|
|
|
Nanoscale
3 publications, 0.99%
|
|
|
Advanced Functional Materials
3 publications, 0.99%
|
|
|
MedComm
3 publications, 0.99%
|
|
|
Journal of Translational Medicine
3 publications, 0.99%
|
|
|
Nature Communications
3 publications, 0.99%
|
|
|
Science advances
3 publications, 0.99%
|
|
|
Biomaterials Science
3 publications, 0.99%
|
|
|
Scientific Reports
3 publications, 0.99%
|
|
|
Frontiers in Bioengineering and Biotechnology
2 publications, 0.66%
|
|
|
2
4
6
8
10
12
14
|
Publishers
|
10
20
30
40
50
60
70
80
|
|
|
Elsevier
74 publications, 24.42%
|
|
|
Wiley
59 publications, 19.47%
|
|
|
Springer Nature
43 publications, 14.19%
|
|
|
American Chemical Society (ACS)
36 publications, 11.88%
|
|
|
MDPI
26 publications, 8.58%
|
|
|
Royal Society of Chemistry (RSC)
13 publications, 4.29%
|
|
|
Frontiers Media S.A.
12 publications, 3.96%
|
|
|
Cold Spring Harbor Laboratory
9 publications, 2.97%
|
|
|
Taylor & Francis
9 publications, 2.97%
|
|
|
American Association for the Advancement of Science (AAAS)
3 publications, 0.99%
|
|
|
Oxford University Press
2 publications, 0.66%
|
|
|
Tsinghua University Press
2 publications, 0.66%
|
|
|
Walter de Gruyter
2 publications, 0.66%
|
|
|
AIP Publishing
2 publications, 0.66%
|
|
|
Georg Thieme Verlag KG
1 publication, 0.33%
|
|
|
American Society for Microbiology
1 publication, 0.33%
|
|
|
Mary Ann Liebert
1 publication, 0.33%
|
|
|
American Association for Cancer Research (AACR)
1 publication, 0.33%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.33%
|
|
|
Korean Society for Biochemistry and Molecular Biology - BMB Reports
1 publication, 0.33%
|
|
|
OAE Publishing Inc.
1 publication, 0.33%
|
|
|
Science in China Press
1 publication, 0.33%
|
|
|
BMJ
1 publication, 0.33%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.33%
|
|
|
American Physiological Society
1 publication, 0.33%
|
|
|
10
20
30
40
50
60
70
80
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
304
Total citations:
304
Citations from 2024:
281
(92.74%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Zong Y. et al. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy // Advanced Materials. 2023. Vol. 35. No. 51.
GOST all authors (up to 50)
Copy
Zong Y., Lin Y., Wei T., Cheng Q. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy // Advanced Materials. 2023. Vol. 35. No. 51.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1002/adma.202303261
UR - https://doi.org/10.1002/adma.202303261
TI - Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
T2 - Advanced Materials
AU - Zong, Yan
AU - Lin, Yi
AU - Wei, Tuo
AU - Cheng, Qiang
PY - 2023
DA - 2023/11/01
PB - Wiley
IS - 51
VL - 35
PMID - 37196221
SN - 0935-9648
SN - 1521-4095
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Zong,
author = {Yan Zong and Yi Lin and Tuo Wei and Qiang Cheng},
title = {Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy},
journal = {Advanced Materials},
year = {2023},
volume = {35},
publisher = {Wiley},
month = {nov},
url = {https://doi.org/10.1002/adma.202303261},
number = {51},
doi = {10.1002/adma.202303261}
}